NTLA 10-Q report for 2026-03-31

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments.

NTLA 10-Q report for 2026-03-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-4785571 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 40 Erie Street , Suite 130 , Cambridge , Massachusetts 02139 (Address of principal executive offices) (Zip Code) 857 - 285-6200 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trade Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒ The number of shares outstanding of the registrant’s common stock as of April 30, 2026: 139,722,277 shares. PART I - FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2026 and 2025 4 Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2026 and 2025 5 Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 6 Notes to Condensed Consolidated Financial Statements 7 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3. Quantitative and Qualitative Disclosures About Market Risk 27 Item 4. Controls and Procedures . 27 PART II - OTHER INFORMATION Item 1. Legal Proceedings 28 Item 1A. Risk Factors 28 I tem 2. Unregistered Sales of Equity Securities and Use of Proceeds 74 Item 5. Other Information 74 Item 6. Exhibits 75 Signatures 76 2 PART I – FINANCI AL INFORMATION Item 1. Financi al Statements INTELLIA THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (unaudited) (Amounts in thousands except share and per share data) March 31, 2026 December 31, 2025 ASSETS Current assets: Cash and cash equivalents $ 134,697 $ 155,464 Marketable securities 241,289 294,420 Accounts receivable 9,131 9,468 Prepaid expenses and other current assets 81,332 68,359 Total current assets 466,449 527,711 Marketable securities - noncurrent 141,261 155,250 Property and equipment, net 15,516 17,671 Operating lease right-of-use assets 97,543 105,955 Investments and other assets 38,010 35,540 Total assets $ 758,779 $ 842,127 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 18,800 $ 20,252 Accrued expenses 37,920 49,862 Current portion of operating lease liability 19,095 26,480 Current portion of deferred revenue 630 7,290 Total current liabilities 76,445 103,884 Long-term operating lease liability 61,395 66,849 Total liabilities 137,840 170,733 Commitments and contingencies (Note 6) Stockholders’ equity: Common stock, $ 0.0001  par value; 240,000,000  shares authorized at March 31, 2026 and December 31, 2025; 120,447,521  and 116,317,060  shares issued and outstanding at March 3 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3. Quantitative and Qualitative Disclosures About Market Risk 27 Item 4. Controls and Procedures . 27 PART II - OTHER INFORMATION Item 1. Legal Proceedings 28 Item 1A. Risk Factors 28 I tem 2. Unregistered Sales of Equity Securities and Use of Proceeds 74 Item 5. Other Information 74 Item 6. Exhibits 75 Signatures 76 2 PART I – FINANCI AL INFORMATION Item 1. Financi al Statements INTELLIA THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (unaudited) (Amounts in thousands except share and per share data) March 31, 2026 December 31, 2025 ASSETS Current assets: Cash and cash equivalents $ 134,697 $ 155,464 Marketable securities 241,289 294,420 Accounts receivable 9,131 9,468 Prepaid expenses and other current assets 81,332 68,359 Total current assets 466,449 527,711 Marketable securities - noncurrent 141,261 155,250 Property and equipment, net 15,516 17,671 Operating lease right-of-use assets 97,543 105,955 Investments and other assets 38,010 35,540 Total assets $ 758,779 $ 842,127 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 18,800 $ 20,252 Accrued expenses 37,920 49,862 Current portion of operating lease liability 19,095 26,480 Current portion of deferred revenue 630 7,290 Total current liabilities 76,445 103,884 Long-term operating lease liability 61,395 66,849 Total liabilities 137,840 170,733 Commitments and contingencies (Note 6) Stockholders’ equity: Common stock, $ 0.0001  par value; 240,000,000  shares authorized at March 31, 2026 and December 31, 2025; 120,447,521  and 116,317,060  shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 12 12 Additional paid-in capital 3,307,492 3,260,444 Accumulated other comprehensive (loss) income ( 240 ) 1,032 Accumulated deficit ( 2,686,325 ) ( 2,590,094 ) Total stockholders’ equity 620,939 671,394 Total liabilities and stockholders’ equity $ 758,779 $ 842,127 See notes to condensed consolidated financial statements. 3 INTELLIA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (Amounts in thousands except per share data) Three Months Ended March 31, 2026 2025 Collaboration revenue $ 15,048 $ 16,627 Operating expenses: Research and development 80,737 108,427 General and administrative 34,843 29,007 Total operating expenses 115,580 137,434 Operating loss ( 100,532 ) ( 120,807 ) Other income, net: Interest income 5,205 8,603 Change in fair value of investments, net ( 904 ) ( 2,125 ) Total other income, net 4,301 6,478 Net loss $ ( 96,231 ) $ ( 114,329 ) Net loss per share, basic and diluted $ ( 0.81 ) $ ( 1.10 ) Weighted average shares outstanding, basic and    diluted 118,490 103,500 Other comprehensive loss: Unrealized (loss) gain on marketable securities ( 1,272 ) 452 Comprehensive loss $ ( 97,503 ) $ ( 113,877 ) See notes to condensed consolidated financial statements. 4 INTELLIA THERAPEUTICS, INC. Condensed Consolidated Statemen ts of Stockholders’ Equity (unaudited) (Amounts in thousands except share data) Additional Accumulated Other Total Common Paid-In Comprehensive Accumulated Stockholders’ Shares Amount Capital Income (Loss) Deficit Equity Balance at December 31, 2025 116,317,060 $ 12 $ 3,260,444 $ 1,032 $ ( 2,590,094 ) $ 671,394 Issuance of common stock through at-the-market offerings, net    of issuance costs of $ 222 2,612,344 - 33,569 - - 33,569 Vesting of restricted stock units 1,518,117 - - - - - Stock-based compensation - - 13,479 - - 13,479 Other comprehensive income (loss) - unrealized loss on    marketable securities - - - ( 1,272 ) - ( 1,272 ) Net loss - - - - ( 96,231 ) ( 96,231 ) Balance at March 31, 2026 120,447,521 $ 12 $ 3,307,492 $ ( 240 ) $ ( 2,686,325 ) $ 620,939 Additional Accumulated Other Total Common Paid-In Comprehensive Accumulated Stockholders’ Shares Amount Capital Income (Loss) Deficit Equity Balance at December 31, 2024 102,029,594 $ 10 $ 3,048,741 $ 605 $ ( 2,177,400 ) $ 871,956 Vesting of restricted stock units 1,510,091 - - - - - Stock-based compensation - - 21,840 - - 21,840 Other comprehensive income (loss) - unrealized gain on    marketable securities - - - 452 - 452 Net loss - - - - ( 114,329 ) ( 114,329 ) Balance at March 31, 2025 103,539,685 $ 10 $ 3,070,581 $ 1,057 $ ( 2,291,729 ) $ 779,919 See notes to condensed consolidated financial statements. 5 INTELLIA THERAPEUTICS, INC. Condensed Consolidated Statements of Cash Flows (unaudited) (Amounts in thousands) Three Months Ended March 31, 2026 2025 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 96,231 ) $ ( 114,329 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 2,202 2,498 Stock-based compensation 13,479 21,840 Accretion of investment discounts ( 535 ) ( 2,280 ) Change in fair value of investments, net 904 2,125 Changes in operating assets and liabilities: Accounts receivable 337 ( 1,987 ) Prepaid expenses and other current assets ( 12,972 ) 218 Operating lease right-of-use assets 8,411 7,218 Other assets ( 74 ) ( 13,826 ) Accounts payable ( 1,420 ) ( 1,869 ) Accrued expenses ( 11,947 ) ( 14,415 ) Deferred revenue ( 6,660 ) ( 5,095 ) Operating lease liabilities ( 12,840 ) ( 29,028 ) Net cash used in operating activities ( 117,346 ) ( 148,930 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property and equipment ( 79 ) ( 735 ) Purchases of marketable securities ( 46,965 ) ( 83,209 ) Sales and maturities of marketable securities 113,354 178,272 Net cash provided by investing activities 66,310 94,328 CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from issuance of common stock through at-the-market offerings 33,569 - Net cash provided by financing activities 33,569 - Net decrease in cash, cash equivalents and restricted cash equivalents ( 17,467 ) ( 54,602 ) Cash, cash equivalents and restricted cash equivalents, beginning of period 167,568 202,787 Cash, cash equivalents and restricted cash equivalents, end of period $ 150,101 $ 148,185 Reconciliation of cash, cash equivalents and restricted cash    equivalents to condensed consolidated balance sheet: Cash and cash equivalents $ 134,697 $ 126,880 Restricted cash equivalents, included in prepaid expenses and other current assets, and    investments and other assets 15,404 21,305 Total cash, cash equivalents and restricted cash equivalents $ 150,101 $ 148,185 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Purchases of property and equipment unpaid at period end $ - $ 82 Reduction of right-of-use assets from remeasurement of lease liabilities - 61,917 See notes to condensed consolidated financial statements. 6 INTELLIA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements (unaudited) 1. Overview and Basis of Presentation Intellia Therapeutics, Inc. (“Intellia,” or the “Company”) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The Company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. For over a decade, Intellia has applied its proprietary technologies and expertise, including CRISPR-based gene editing technologies, oligonucleotides, and lipid nanoparticles (“LNPs”), to develop novel, first-in-class product candidates. This includes the development of lonvoguran ziclumeran (“lonvo-z,” previously referred to as NTLA-2002) for the treatment of hereditary angioedema (“HAE”) and nexiguran ziclumeran (“nex-z,” previously referred to as NTLA-2001) for the treatment of transthyretin (“ATTR”) amyloidosis. These lead product candidates are the first in vivo genome editing product candidates to advance into Phase 3 clinical development. These systemically administered CRISPR-based candidates are designed to address diseases with high unmet need with a single intravenous (“IV”) infusion that is administered in an outpatient setting. In April 2026, the Company reported positive topline data from the global Phase 3 HAELO clinical trial of lonvo-z in HAE, and preparations are underway for the planned commercial launch of lonvo-z in the first half of 2027. The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K (“Annual Report”) for the year ended December 31, 2025. The unaudited condensed consolidated financial statements include the accounts of Intellia Therapeutics, Inc. and its wholly- owned subsidiary, Intellia Securities Corp. All intercompany balances and transactions have been eliminated in consolidation. Comprehensive loss is comprised of net loss and unrealized gain/loss on marketable securities. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, research and development expenses and stock-based compensation expense. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances at the time such estimates are made. Actual results could differ from those estimates. The Company periodically reviews its estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if any, would be reflected in the condensed consolidated financial statements prospectively from the date of the change in estimate. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. Liquidity Since its inception through March 31, 2026, the Company has funded its operations through its initial public offering (“IPO”) and concurrent private placements, follow-on public offerings, at-the-market offerings and the sale of convertible preferred stock, as well as through its collaboration agreements. The Company expects that its cash, cash equivalents and marketable securities as of March 31, 2026 will enable the Company to fund its ongoing operating expenses and capital expenditure requirements for at least the twelve-month period following the issuance of these condensed consolidated financial statements. 7 2. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies” to the consolidated financial statements included in its Annual Report for the year ended December 31, 2025. There have been no material changes to these policies in the three months ended March 31, 2026. Recently Issued Accounting Pronouncements Not Yet Effective In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires disclosure of specified information about certain costs and expenses in the footnotes to the financial statements. This ASU is effective for annual periods beginning after December 15, 2026 and is applicable to the Company’s fiscal year beginning January 1, 2027, with early application permitted. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures. In December 2025, the FASB issued ASU No. 2025-12, Codification Improvements. This ASU’s purpose is to update the FASB’s Accounting Standard Codification (“ASC”) for a broad range of topics in order to clarify, correct errors, or make minor improvements that make the ASC easier to understand and apply. This ASU is effective for interim reporting periods within annual periods beginning after December 15, 2026 and is applicable to the Company’s fiscal year beginning January 1, 2027. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures . 3. Marketable Securit Item 1A. Risk Factors 28 I tem 2. Unregistered Sales of Equity Securities and Use of Proceeds 74 Item 5. Other Information 74 Item 6. Exhibits 75 Signatures 76 2 PART I – FINANCI AL INFORMATION Item 1. Financi al Statements INTELLIA THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (unaudited) (Amounts in thousands except share and per share data) March 31, 2026 December 31, 2025 ASSETS Current assets: Cash and cash equivalents $ 134,697 $ 155,464 Marketable securities 241,289 294,420 Accounts receivable 9,131 9,468 Prepaid expenses and other current assets 81,332 68,359 Total current assets 466,449 527,711 Marketable securities - noncurrent 141,261 155,250 Property and equipment, net 15,516 17,671 Operating lease right-of-use assets 97,543 105,955 Investments and other assets 38,010 35,540 Total assets $ 758,779 $ 842,127 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 18,800 $ 20,252 Accrued expenses 37,920 49,862 Current portion of operating lease liability 19,095 26,480 Current portion of deferred revenue 630 7,290 Total current liabilities 76,445 103,884 Long-term operating lease liability 61,395 66,849 Total liabilities 137,840 170,733 Commitments and contingencies (Note 6) Stockholders’ equity: Common stock, $ 0.0001  par value; 240,000,000  shares authorized at March 31, 2026 and December 31, 2025; 120,447,521  and 116,317,060  shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 12 12 Additional paid-in capital 3,307,492 3,260,444 Accumulated other comprehensive (loss) income ( 240 ) 1,032 Accumulated deficit ( 2,686,325 ) ( 2,590,094 ) Total stockholders’ equity 620,939 671,394 Total liabilities and stockholders’ equity $ 758,779 $ 842,127 See notes to condensed consolidated financial statements. 3 INTELLIA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (Amounts in thousands except per share data) Three Months Ended March 31, 2026 2025 Collaboration revenue $ 15,048 $ 16,627 Operating expenses: Research and development 80,737 108,427 General and administrative 34,843 29,007 Total operating expenses 115,580 137,434 Operating loss ( 100,532 ) ( 120,807 ) Other income, net: Interest income 5,205 8,603 Change in fair value of investments, net ( 904 ) ( 2,125 ) Total other income, net 4,301 6,478 Net loss $ ( 96,231 ) $ ( 114,329 ) Net loss per share, basic and diluted $ ( 0.81 ) $ ( 1.10 ) Weighted average shares outstanding, basic and    diluted 118,490 103,500 Other comprehensive loss: Unrealized (loss) gain on marketable securities ( 1,272 ) 452 Comprehensive loss $ ( 97,503 ) $ ( 113,877 ) See notes to condensed consolidated financial statements. 4 INTELLIA THERAPEUTICS, INC. Condensed Consolidated Statemen ts of Stockholders’ Equity (unaudited) (Amounts in thousands except share data) Additional Accumulated Other Total Common Paid-In Comprehensive Accumulated Stockholders’ Shares Amount Capital Income (Loss) Deficit Equity Balance at December 31, 2025 116,317,060 $ 12 $ 3,260,444 $ 1,032 $ ( 2,590,094 ) $ 671,394 Issuance of common stock through at-the-market offerings, net    of issuance costs of $ 222 2,612,344 - 33,569 - - 33,569 Vesting of restricted stock units 1,518,117 - - - - - Stock-based compensation - - 13,479 - - 13,479 Other comprehensive income (loss) - unrealized loss on    marketable securities - - - ( 1,272 ) - ( 1,272 ) Net loss - - - - ( 96,231 ) ( 96,231 ) Balance at March 31, 2026 120,447,521 $ 12 $ 3,307,492 $ ( 240 ) $ ( 2,686,325 ) $ 620,939 Additional Accumulated Other Total Common Paid-In Comprehensive Accumulated Stockholders’ Shares Amount Capital Income (Loss) Deficit Equity Balance at December 31, 2024 102,029,594 $ 10 $ 3,048,741 $ 605 $ ( 2,177,400 ) $ 871,956 Vesting of restricted stock units 1,510,091 - - - - - Stock-based compensation - - 21,840 - - 21,840 Other comprehensive income (loss) - unrealized gain on    marketable securities - - - 452 - 452 Net loss - - - - ( 114,329 ) ( 114,329 ) Balance at March 31, 2025 103,539,685 $ 10 $ 3,070,581 $ 1,057 $ ( 2,291,729 ) $ 779,919 See notes to condensed consolidated financial statements. 5 INTELLIA THERAPEUTICS, INC. Condensed Consolidated Statements of Cash Flows (unaudited) (Amounts in thousands) Three Months Ended March 31, 2026 2025 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 96,231 ) $ ( 114,329 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 2,202 2,498 Stock-based compensation 13,479 21,840 Accretion of investment discounts ( 535 ) ( 2,280 ) Change in fair value of investments, net 904 2,125 Changes in operating assets and liabilities: Accounts receivable 337 ( 1,987 ) Prepaid expenses and other current assets ( 12,972 ) 218 Operating lease right-of-use assets 8,411 7,218 Other assets ( 74 ) ( 13,826 ) Accounts payable ( 1,420 ) ( 1,869 ) Accrued expenses ( 11,947 ) ( 14,415 ) Deferred revenue ( 6,660 ) ( 5,095 ) Operating lease liabilities ( 12,840 ) ( 29,028 ) Net cash used in operating activities ( 117,346 ) ( 148,930 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property and equipment ( 79 ) ( 735 ) Purchases of marketable securities ( 46,965 ) ( 83,209 ) Sales and maturities of marketable securities 113,354 178,272 Net cash provided by investing activities 66,310 94,328 CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds from issuance of common stock through at-the-market offerings 33,569 - Net cash provided by financing activities 33,569 - Net decrease in cash, cash equivalents and restricted cash equivalents ( 17,467 ) ( 54,602 ) Cash, cash equivalents and restricted cash equivalents, beginning of period 167,568 202,787 Cash, cash equivalents and restricted cash equivalents, end of period $ 150,101 $ 148,185 Reconciliation of cash, cash equivalents and restricted cash    equivalents to condensed consolidated balance sheet: Cash and cash equivalents $ 134,697 $ 126,880 Restricted cash equivalents, included in prepaid expenses and other current assets, and    investments and other assets 15,404 21,305 Total cash, cash equivalents and restricted cash equivalents $ 150,101 $ 148,185 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Purchases of property and equipment unpaid at period end $ - $ 82 Reduction of right-of-use assets from remeasurement of lease liabilities - 61,917 See notes to condensed consolidated financial statements. 6 INTELLIA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements (unaudited) 1. Overview and Basis of Presentation Intellia Therapeutics, Inc. (“Intellia,” or the “Company”) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The Company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. For over a decade, Intellia has applied its proprietary technologies and expertise, including CRISPR-based gene editing technologies, oligonucleotides, and lipid nanoparticles (“LNPs”), to develop novel, first-in-class product candidates. This includes the development of lonvoguran ziclumeran (“lonvo-z,” previously referred to as NTLA-2002) for the treatment of hereditary angioedema (“HAE”) and nexiguran ziclumeran (“nex-z,” previously referred t Results of Operations 19 Item 3. Quantitative and Qualitative Disclosures About Market Risk 27 Item 4. Controls and Procedures . 27 PART II - OTHER INFORMATION Item 1. Legal Proceedings 28 Item 1A. Risk Factors 28 I tem 2. Unregistered Sales of Equity Securities and Use of Proceeds 74 Item 5. Other Information 74 Item 6. Exhibits 75 Signatures 76 2 PART I – FINANCI AL INFORMATION Item 1. Financi al Statements INTELLIA THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (unaudited) (Amounts in thousands except share and per share data) March 31, 2026 December 31, 2025 ASSETS Current assets: Cash and cash equivalents $ 134,697 $ 155,464 Marketable securities 241,289 294,420 Accounts receivable 9,131 9,468 Prepaid expenses and other current assets 81,332 68,359 Total current assets 466,449 527,711 Marketable securities - noncurrent 141,261 155,250 Property and equipment, net 15,516 17,671 Operating lease right-of-use assets 97,543 105,955 Investments and other assets 38,010 35,540 Total assets $ 758,779 $ 842,127 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 18,800 $ 20,252 Accrued expenses 37,920 49,862 Current portion of operating lease liability 19,095 26,480 Current portion of deferred revenue 630 7,290 Total current liabilities 76,445 103,884 Long-term operating lease liability 61,395 66,849 Total liabilities 137,840 170,733 Commitments and contingencies (Note 6) Stockholders’ equity: Common stock, $ 0.0001  par value; 240,000,000  shares authorized at March 31, 2026 and December 31, 2025; 120,447,521  and 116,317,060  shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 12 12 Additional paid-in capital 3,307,492 3,260,444 Accumulated other comprehensive (loss) income ( 240 ) 1,032 Accumulated deficit ( 2,686,325 ) ( 2,590,094 ) Total stockholders’ equity 620,939 671,394 Total liabilities and stockholders’ equity $ 758,779 $ 842,127 See notes to condensed consolidated financial statements. 3 INTELLIA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (Amounts in thousands except per share data) Three Months Ended March 31, 2026 2025 Collaboration revenue $ 15,048 $ 16,627 Operating expenses: Research and development 80,737 108,427 General and administrative 34,843 29,007 Total operating expenses 115,580 137,434 Operating loss ( 100,532 ) ( 120,807 ) Other income, net: Interest income 5,205 8,603 Change in fair value of investments, net ( 904 ) ( 2,125 ) Total other income, net 4,301 6,478 Net loss $ ( 96,231 ) $ ( 114,329 ) Net loss per share, basic and diluted $ ( 0.81 ) $ ( 1.10 ) Weighted average shares outstanding, basic and    diluted 118,490 103,500 Other comprehensive loss: Unrealized (loss) gain on marketable securities ( 1,272 ) 452 Comprehensive loss $ ( 97,503 ) $ ( 113,877 ) See notes to condensed consolidated financial statements. 4 INTELLIA THERAPEUTICS, INC. Condensed Consolidated Statemen ts of Stockholders’ Equity (unaudited) (Amounts in thousands except share data) Additional Accumulated Other Total Common Paid-In Comprehensive Accumulated Stockholders’ Shares Amount Capital Income (Loss) Deficit Equity Balance at December 31, 2025 116,317,060 $ 12 $ 3,260,444 $ 1,032 $ ( 2,590,094 ) $ 671,394 Issuance of common stock through at-the-market offerings, net    of issuance costs of $ 222 2,612,344 - 33,569 - - 33,569 Vesting of restricted stock units 1,518,117 - - - - - Stock-based compensation - - 13,479 - - 13,479 Other comprehensive income (loss) - unrealized loss on    marketable securities - - - ( 1,272 ) - ( 1,272 ) Net loss - - - - ( 96,231 ) ( 96,231 ) Balance at March 31, 2026 120,447,521 $ 12 $ 3,307,492 $ ( 240 ) $ ( 2,686,325 ) $ 620,939 Additional Accumulated Other Total Common Paid-In Comprehensive Accumulated Stockholders’ Shares Amount Capital Income (Loss) Deficit Equity Balance at December 31, 2024 102,029,594 $ 10 $ 3,048,741 $ 605 $ ( 2,177,400 ) $ 871,956 Vesting of restricted stock units 1,510,091 - - - - - Stock-based compensation - - 21,840 - - 21,840 Other comprehensive income (loss) - unrealized gain on    marketable securities - - - 452 - 452 Net loss - - - - ( 114,329 ) ( 114,329 ) Balance at March 31, 2025 103,539,685 $ 10 $ 3,070,581 $ 1,057 $ ( 2,291,729 ) $ 779,919 See notes to condensed consolidated financial statements. 5 INTELLIA THERAPEUTICS, INC. Condensed Consolidated Statements of Cash Flows (unaudited) (Amounts in thousands) Three Months Ended March 31, 2026 2025 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 96,231 ) $ ( 114,329 ) Adjustments to reconcile net loss to net cash used in

The provided excerpt is only the Form 10‑Q cover page for GE Vernova Inc. (GEV) for quarter ended 2026‑06‑30, with no financial statements, MD&A, segment results, guidance, backlog, risks, or other performance details included. As-is, it contains almost no trade-relevant incremental information beyond confirming the filing/period and listing details.

This excerpt is only the cover page/header of Sleep Number’s Form 10-Q for the quarter ended April 4, 2026. It contains filing metadata (issuer, ticker, exchange, address) but no financial statements, MD&A, guidance, risks, or operational commentary. As a result, it is not directly actionable for trading beyond confirming the filing exists.

The provided excerpt is only the cover/filing header of SoundHound AI, Inc.’s 10‑Q for the quarter ended 2026‑03‑31. It contains listing/security identifiers (SOUN, SOUNW) but no financial statements, MD&A, guidance, risk updates, liquidity details, or material events. As a result, there is insufficient information to form high-confidence, actionable bullish/bearish theses beyond generic “company filed its 10‑Q” metadata.

The provided excerpt is only the boilerplate cover/filing-status section of Teucrium Commodity Trust’s Form 10‑Q for period ended 2026‑03‑31, with no portfolio holdings, performance, risk, or material updates included. As-is, it contains no actionable investment information beyond confirming the existence of the filing and the issuer/ticker identity (WEAT).

The provided text is only the cover/header portion of Archer Aviation’s Form 10‑Q for the quarter ended 2026‑03‑31 (issuer identity, exchange listing, and securities outstanding). It contains no operating/financial results, guidance, liquidity details, backlog, or risk-factor updates—so it is minimally actionable for trading beyond basic security identifiers and a generic dilution/optionality consideration from warrants.

This excerpt is essentially the cover page of CleanSpark, Inc.’s Form 10-Q for the quarter ended March 31, 2026. It contains identifiers (CIK/file no.), listing venue, and security descriptions (common stock and redeemable warrants with specific exercise terms), but no operating/financial results, guidance, risks, or MD&A detail. Actionability is therefore limited to capital-structure/dilution considerations around the listed warrant.

This excerpt of AST SpaceMobile’s 10‑Q is largely SEC cover-page/boilerplate (registrant info, exchange listing, filing compliance) and contains no financial results, guidance, liquidity, risk-factor updates, or operating metrics. As provided, it does not create a clear tradable catalyst beyond confirming continued reporting/listing status.

This excerpt only includes the cover page of Super Micro Computer, Inc.’s Form 10‑Q for the quarter ended March 31, 2026. It confirms the filing, issuer identity, listing (Nasdaq), and ticker (SMCI), but contains no financial results, guidance, risks, or MD&A content to support a directional investment view.